Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of conditionally activated biologic therapeutics for cancer treatment. The company operates within the oncology and biotechnology industries, with its core innovation centered on its proprietary Probody® therapeutic platform, which is designed to improve the safety and efficacy of antibody-based cancer therapies by activating them primarily within the tumor microenvironment.
CytomX’s primary business involves advancing an internal oncology pipeline while also partnering with large pharmaceutical companies to co-develop Probody-enabled therapeutics. Its strategic positioning is based on reducing off-tumor toxicity, a key limitation of conventional antibody and immune therapies. Founded in 2008, CytomX evolved from an early research-focused company into a publicly traded clinical-stage organization following its initial public offering in 2015, progressively shifting toward late preclinical and clinical development through both internal programs and collaborations.
Business Operations
CytomX operates primarily as a clinical-stage research and development organization, generating value through the advancement of proprietary drug candidates and through collaboration agreements that include upfront payments, research funding, milestone payments, and potential royalties. The company’s operations are organized around its Probody® Therapeutic Platform and its oncology pipeline, which includes antibody-drug conjugates, T-cell engagers, and immune-modulating antibodies.
The company conducts most of its research and development activities internally in the United States, while leveraging strategic partnerships for later-stage development and commercialization. Notable collaborators have included AbbVie, Bristol Myers Squibb, and Amgen, under agreements that allow partners to apply Probody technology to specific targets. CytomX does not currently manufacture or commercialize products at scale, relying instead on third-party manufacturers and clinical research organizations.
Strategic Position & Investments
CytomX’s strategic direction emphasizes advancing wholly owned pipeline programs while selectively partnering assets that align with external development expertise. Key growth initiatives include the clinical advancement of internal Probody therapeutics and the expansion of the platform into bispecific antibodies and other next-generation immune-oncology modalities.
A major strategic investment has been the continued development of ABBV‑011 (formerly CX‑2029), an antibody-drug conjugate partnered with AbbVie, which targets solid tumors. CytomX has also invested heavily in earlier-stage Probody T-cell engagers, including CX‑904, although public disclosures indicate that program ownership, partner involvement, and development timelines have evolved, and some details remain data inconclusive based on available public sources. Overall, the company’s portfolio strategy reflects a balance between internal innovation and risk-sharing partnerships.
Geographic Footprint
CytomX Therapeutics is headquartered in South San Francisco, California, a major biotechnology hub within the United States. The company’s core research, development, and administrative operations are primarily U.S.-based, with no large-scale commercial operations in other regions.
International exposure is achieved indirectly through global pharmaceutical partners, whose clinical trials and potential commercialization activities extend CytomX-derived technologies into Europe, Asia, and other global oncology markets. While CytomX itself maintains a limited physical international presence, its platform has global reach through these collaborative arrangements.
Leadership & Governance
CytomX was founded by Steve Furfine, who played a central role in the development of the Probody platform and continues to influence the company’s scientific direction. The leadership team emphasizes a strategy of scientific rigor, disciplined capital allocation, and partnership-driven development to advance innovative oncology therapeutics while managing clinical and financial risk.
Key members of CytomX leadership include:
- Sean McCarthy – President & Chief Executive Officer
- Steve Furfine – Founder & Chief Scientific Officer
- Nancy Lurker – Executive Chair of the Board
Public disclosures identify additional executive and board leadership; however, certain role definitions and tenure details beyond these individuals are data inconclusive based on available public sources.